Malignant hyperthermia (MH) is a rare, but severe anesthetic complication triggered by certain medications used during general anesthesia. This condition causes uncontrolled muscle contraction, rapidly rising body temperature, and severe metabolic complications. Although MH is uncommon, it can be fatal if not recognized and treated quickly. The condition is genetic, meaning it can run in families and may occur even in individuals who previously tolerated anesthesia without issues. Understanding the symptoms, causes, and genetic risk factors of malignant hyperthermia can help patients and healthcare providers prevent serious complications during surgery.
When exposed to triggering agents, the body's skeletal muscles enter a hypermetabolic state, leading to:
- Continuous muscle contraction
- Rapid increase in body temperature
- Increased carbon dioxide levels
- Metabolic acidosis
- Muscle breakdown (rhabdomyolysis)
If untreated, MH may lead to kidney failure, cardiac arrhythmia, multiple organ failure, and/or death.
MH is usually triggered by:
- Volatile inhalational anesthetics (halogenated anesthetic agents)
- The muscle relaxant succinylcholine
The condition is most commonly associated with mutations in genes responsible for calcium regulation in muscle cells.
Symptoms of Malignant Hyperthermia
Malignant Hyperthermia typically occurs during or shortly after anesthesia. Early detection is critical.
Common symptoms include:
- Rapidly rising body temperature; body temperature can increase dramatically, sometimes exceeding 43°C (110°F).
- Muscle rigidity; persistent muscle stiffness, especially jaw muscle rigidity (masseter spasm).
- Rapid or Irregular Heartbeat
Patients may develop:
- Sinus tachycardia
- Ventricular tachycardia
- Ventricular fibrillation
- Elevated carbon dioxide levels (hypercapnia)
Early warning signs of MH
- Metabolic acidosis; the blood becomes overly acidic due to excessive metabolic activity.
- Dark urine; muscle breakdown can cause dark-colored urine, a sign of rhabdomyolysis.
What Causes Malignant Hyperthermia?
Malignant Hyperthermia is primarily caused by genetic mutations affecting calcium regulation in muscle cells.
The condition follows an autosomal dominant inheritance pattern, meaning if one parent carries the gene mutation each child has a 50% chance of inheriting it.
However, many individuals with MH susceptibility have no symptoms in everyday life, making genetic testing important for early detection.
Genes Associated with Malignant Hyperthermia
Several genes are linked to MH susceptibility:
- RYR1 Gene The most common gene mutation; responsible for approximately 70–80% of MH cases. It controls calcium release in muscle cells.
- CACNA1S Gene A calcium channel gene, working together with RYR1. Mutations are relatively rare (about 1% of cases).
- STAC3 Gene Rare mutations associated with congenital muscle disorders and MH susceptibility.
Who Should Consider Genetic Testing for Malignant Hyperthermia?
Genetic testing may help identify individuals at risk before undergoing surgery.
Testing is recommended for:
- Individuals with a family history of MH
- People whose parents, siblings, or close relatives experienced severe reactions to anesthesia.
- Individuals with a personal history of anesthesia complications.
- Individuals with certain muscle disorders<
- Muscle weakness
- Muscle rigidity
- Muscle atrophy
- Exercise-induced muscle breakdown
Genetic Testing for Malignant Hyperthermia
Genetic testing can help detect MH susceptibility.
At Bumrungrad International Hospital, several advanced genomic testing options are available.
These include:
- Whole Exome Sequencing (WES) — Comprehensive sequencing of protein-coding genes to evaluate genetic risk factors for multiple diseases, including MH.
- Whole Genome Sequencing (WGS) — Advanced testing that analyzes the entire genome to assess risks for multiple conditions such as cancer, cardiovascular disease, and MH.
- Targeted Genetic Panel Testing — Focused testing of specific MH-related genes, including:
Results are typically available in 4–8 weeks, depending on the testing method.
Treatment of Malignant Hyperthermia
Malignant hyperthermia is a medical emergency requiring immediate treatment.
Standard management techniques includes:
- Stopping administering anesthetic agents
- All triggering anesthesia medications must be discontinued immediately.
- Administering dantrolene
- Dantrolene is the only medication proven to directly treat MH.
Cooling measures may include:
- Cooling blankets
- Cold saline infusion
- Temperature control devices
- Managing complications
Treatment may also include management of:
- Cardiac arrhythmias
- Metabolic acidosis
- Kidney injury
Patients are typically monitored in an Intensive Care Unit (ICU) after treatment.
Malignant Hyperthermia Safety Protocols in Hospitals
Leading hospitals follow strict safety protocols to detect and treat MH.
At Bumrungrad International Hospital, patient safety protocols follow international standards of the Joint Commission International, including:
- Pre-operative anesthesia risk assessment
- Immediate availability of dantrolene in operating rooms
- Dedicated malignant hyperthermia emergency cart
- Continuous monitoring of CO₂ levels, body temperature, and heart rhythm
- Total Intravenous Anesthesia (TIVA) for high-risk patients
- ICU support for post-operative monitoring
Frequently Asked Questions About Malignant Hyperthermia
Q: Is Malignant Hyperthermia the same as a fever?
A: No. MH is not caused by infection. It is a metabolic reaction in muscle cells that generates uncontrolled heat inside the body.
Q: Can someone develop MH even if previous surgeries were normal?
A: Yes. Some individuals with MH susceptibility may undergo anesthesia several times without issues before experiencing an MH crisis.
Q: Can patients with MH genes still undergo surgery?
A: Yes. Surgery can be performed safely using total intravenous anesthesia (TIVA), which avoids triggering anesthetic agents.
Q: What is Dantrolene?
A: Dantrolene is the only medication that is effective in treating malignant hyperthermia. It works by preventing excessive calcium release in muscle cells.
Q: How long does MH genetic testing take?
A: Testing requires a blood sample and typically takes 4–8 weeks using next-generation sequencing.
Online Consultation with Geneticists / Genetic Counselors
By Prof. Dr. Chonlaphat Sukasem, Pharmacogenetics Consultant at Bumrungrad International Hospital